At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

EpiPens are a life-saving treatment for severe allergic reactions. Indiana's AG says Pfizer and Mylan have broken the law to ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...